Compare Amgen, Inc. (AMGN) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Synopsys, Inc. — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Synopsys, Inc. trades at $454.05 (market cap $85.30B). The key difference: Amgen, Inc. is far larger — about 2.3× Synopsys, Inc.'s market cap, and Amgen, Inc. pays a 2.77% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.
| AMGN | SNPS | |
|---|---|---|
Market Cap | $196.12B | $85.30B |
Sector | Health | Technology |
52-Week High | $388.16 | $645.59 |
52-Week Low | $271.18 | $380.47 |
Enterprise Value | $241.41B | $93.66B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Synopsys (SNPS) trades at $445.40, up 0.5% on the day, amid a bearish technical signal with support at $432 and resistance at $449. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $3.35 versus $3.15 expected, and robust revenue growth to $7.05B in 2025. However, net income margin declined to 8.91% from 36.93% in 2024, and cash flow turned negative at -$1.01B due to heavy investing activity.
Outlook remains positive with analyst consensus price target of $558.33 implying 25% upside, supported by the company's strategic pivot to AI-driven design tools. Key risks include execution of the AI transition, high valuation multiples like a P/E of 101.95, and semiconductor cycle volatility. The stock offers growth exposure but requires monitoring of margin trends and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
